

# Remifentanyl

## A Review of its Analgesic and Sedative Use in the Intensive Care Unit

Anna J. Battershill and Gillian M. Keating

Adis International Limited, Auckland, New Zealand

### Various sections of the manuscript reviewed by:

*F. Cavaliere*, Institute of Anaesthesia and Intensive Care, Catholic University of the Sacred Heart, Rome, Italy; *T. Chinachoti*, Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; *A.A. Dahaba*, Department of Anaesthesiology and Intensive Care Medicine, Graz University, Graz, Austria; *M. Howie*, Department of Anesthesiology, Ohio State University Medical Center, Columbus, Ohio, USA; *A. Karabinis*, Intensive Care Unit, General Hospital G. Gennimatas, Athens, Greece; *L.L. Liu*, Department of Anesthesia and Perioperative Care, University of California-San Francisco, San Francisco, California, USA; *M.L. Malbrain*, Intensive Care Unit, Ziekenhuis Netwerk Antwerpen, Antwerpen, Belgium; *B. Müllejans*, Klinik für Anaesthesiologie und Intensivmedizin, Klinikum Karlsburg, Herz-und Diabeteszentrum Mecklenburg-Vorpommern, Karlsburg, Germany; *S. Soltész*, Klinik für Anästhesie und operative Intensivmedizin, Klinikum Leverkusen, Leverkusen, Germany.

### Data Selection

**Sources:** Medical literature published in any language since 1980 on 'remifentanyl', identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

**Search strategy:** MEDLINE search terms were 'remifentanyl' and ('intensive care' or 'intensive care units' or 'ICU' or 'critical care') and ('sedation' or 'analgesia'). EMBASE search terms were 'remifentanyl' or ('intensive care' or 'intensive care units' or 'ICU' or 'critical care') and ('sedation' or 'analgesia'). AdisBase search terms were 'remifentanyl' or ('intensive-care-units' or 'intensive care' or 'ICU' or 'critical care') and ('sedation' or 'analgesia'). Searches were last updated 23 January 2006.

**Selection:** Studies in patients admitted to the intensive care unit who received remifentanyl. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.

**Index terms:** Remifentanyl, analgesia, sedation, intensive care, pharmacodynamics, pharmacokinetics, therapeutic use.

## Contents

|                                                                            |     |
|----------------------------------------------------------------------------|-----|
| Summary                                                                    | 366 |
| 1. Introduction                                                            | 368 |
| 2. Pharmacodynamic Properties                                              | 368 |
| 3. Pharmacokinetic Properties                                              | 370 |
| 3.1 Special Patient Populations                                            | 372 |
| 4. Therapeutic Efficacy                                                    | 372 |
| 4.1 Efficacy in Mechanically Ventilated Intensive Care Unit (ICU) Patients | 372 |
| 4.1.1 Early Trials                                                         | 372 |
| 4.1.2 Comparisons with Other Opioids                                       | 373 |
| 4.1.3 In Paediatric Patients                                               | 377 |
| 4.2 Efficacy During Other Painful Procedures in ICU Patients               | 378 |
| 5. Tolerability                                                            | 379 |
| 5.1 In Adult Patients                                                      | 379 |

|                                                                                    |     |
|------------------------------------------------------------------------------------|-----|
| 5.2 In Paediatric Patients . . . . .                                               | 380 |
| 6. Pharmacoeconomic Considerations . . . . .                                       | 380 |
| 7. Dosage and Administration . . . . .                                             | 380 |
| 8. Place of Remifentanyl When Used for Analgesia and Sedation in the ICU . . . . . | 381 |

## Summary

### Abstract

Remifentanyl (Ultiva™), a 4-anilidopiperidine derivative of fentanyl, is an ultra-short-acting  $\mu$ -opioid receptor agonist indicated to provide analgesia and sedation in mechanically ventilated intensive care unit (ICU) patients.

Analgesia-based sedation with remifentanyl is a useful option for mechanically ventilated patients in the ICU setting. Its unique properties (e.g. organ-independent metabolism, lack of accumulation, rapid offset of action) set it apart from other opioid agents. Remifentanyl is at least as effective as comparator opioids such as fentanyl, morphine and sufentanyl in providing pain relief and sedation in mechanically ventilated ICU patients. Moreover, it allows fast and predictable extubation, as well as being associated with a shorter duration of mechanical ventilation and quicker ICU discharge than comparators in some studies. In addition, remifentanyl is generally well tolerated in this patient population. Thus, remifentanyl is a welcome addition to the currently available pharmacological agents employed in the management of mechanically ventilated ICU patients.

### Pharmacological Properties

Remifentanyl is a 4-anilidopiperidine derivative of fentanyl containing an ester linkage to propanoic acid. It is ultra-short acting and displays analgesic effects, consistent with its agonist activity at the  $\mu$ -receptor. The primary metabolite, remifentanyl acid, has negligible activity compared with remifentanyl. Remifentanyl has a rapid onset of action ( $\approx 1$  minute) and a rapid offset of action following discontinuation ( $\approx 3$ – $10$  minutes). The time to offset of action was not prolonged to a clinically significant extent by renal impairment or prolonged infusion in post-surgical or medical ICU patients who received remifentanyl for up to 72 hours. In mechanically ventilated ICU patients, the median time to offset of action was significantly shorter with remifentanyl than with morphine or fentanyl after 10 days' treatment.

The effect of remifentanyl on haemodynamics is typical of opioids (e.g. decreased blood pressure and heart rate). In ICU patients, remifentanyl was generally associated with an acceptable degree of haemodynamic stability. There were no significant differences between remifentanyl, fentanyl and morphine recipients in mean intracranial pressure (ICP) or cerebral perfusion pressure in mechanically ventilated ICU patients with acute brain injury or who had undergone neurosurgery. However, compared with baseline, ICP was significantly increased and cerebral perfusion pressure was significantly reduced with remifentanyl in mechanically ventilated patients with severe traumatic brain injury in another study.

Remifentanyl is rapidly distributed throughout the body and demonstrates linear, dose-dependent, multicompartmental pharmacokinetics. The drug undergoes widespread extravascular metabolism and is rapidly metabolised via extrahepatic, nonspecific blood and tissue esterases to remifentanyl acid. The

pharmacokinetics of remifentanyl were not altered to a clinically significant extent in ICU patients with moderate to severe renal impairment who received the drug for up to 72 hours, compared with ICU patients with normal renal function or mild renal impairment. The pharmacokinetics of remifentanyl were also not altered to a clinically significant extent in patients with severe chronic liver disease. Remifentanyl has a context-sensitive half-time of  $\approx 3\text{--}4$  minutes, irrespective of the duration of infusion. Age-related changes in clearance and volume of distribution occurred in paediatric patients receiving remifentanyl.

---

### Therapeutic Efficacy

A number of well designed trials have compared the use of analgesia-based sedation with remifentanyl with that of morphine, fentanyl or sufentanyl in post-surgical, trauma and/or medical patients ( $n \geq 20$ ) who were being mechanically ventilated in an ICU setting.

Remifentanyl provided effective analgesia-based sedation in mechanically ventilated patients in the ICU setting. Optimal sedation was achieved for  $\geq 78\%$  of the time with remifentanyl. Moreover, with remifentanyl, the duration of optimal sedation and the percentage of hours during which patients had no or mild pain was generally similar to that with fentanyl or morphine. In addition, compared with remifentanyl, the need for additional sedation generally appeared greater with fentanyl and morphine regimens, but not with sufentanyl regimens.

Remifentanyl was at least as effective as fentanyl, morphine and sufentanyl in terms of recovery parameters. In some studies, including a study examining longer-term mechanical ventilation, remifentanyl was associated with a significantly shorter duration of mechanical ventilation than fentanyl or morphine. In addition, remifentanyl was associated with a significantly shorter extubation time than fentanyl, morphine or sufentanyl and a shorter time to ICU discharge than fentanyl or morphine in some studies. Two studies noted an absence of tolerance to remifentanyl, although tolerance was seen in 29% of remifentanyl recipients in another study. A remifentanyl-based regimen may also be associated with savings in staff costs, according to the results of a prospective cost-consequence analysis.

Remifentanyl was associated with rapid and predictable emergence from sedation in mechanically ventilated ICU patients with acute brain injury or who had undergone neurosurgery in a randomised, nonblind study. Significantly less between-patient variability in the time to neurological assessment occurred in patients receiving analgesia-based sedation with remifentanyl than in those receiving hypnotic-based sedation incorporating fentanyl or morphine. Remifentanyl patients requiring mechanical ventilation were extubated significantly earlier than patients receiving the morphine-based regimen. The extubation time and time until ICU discharge were also significantly shorter with remifentanyl plus propofol than with fentanyl plus midazolam in mechanically ventilated ICU patients who had undergone supratentorial brain surgery in a retrospective study.

Remifentanyl provided similar analgesia-based sedation to fentanyl in paediatric patients aged 3–16 years who were being mechanically ventilated following orthopaedic spinal surgery. Remifentanyl also demonstrated efficacy in mechanically ventilated newborns.

Remifentanyl provided adequate analgesia in ICU patients with severe burns during dressing changes, and an intravenous infusion of remifentanyl effectively

reduced stress during endotracheal suctioning in mechanically ventilated post-surgical ICU patients sedated with sufentanil.

## Tolerability

Remifentanyl was generally well tolerated in ICU patients requiring mechanical ventilation. The most commonly occurring adverse events in remifentanyl recipients relate to its  $\mu$ -opioid agonist properties (e.g. bradycardia, hypotension).

The tolerability of remifentanyl was generally similar to that of fentanyl or morphine in ICU patients requiring short-term mechanical ventilation for up to  $\approx 3$  days. In terms of the proportion of patients experiencing drug-related adverse effects, there was no significant difference between remifentanyl and morphine recipients (22% vs 16%), or between remifentanyl and fentanyl recipients (23% vs 17%). Moreover, there was no significant difference between remifentanyl and fentanyl recipients in the incidence of hypotension, nausea, fever or vomiting.

In critically ill patients mechanically ventilated for up to 10 days, drug-related adverse events occurred in 11% of recipients and in 8% of patients receiving a comparator regimen (midazolam with fentanyl or morphine). The most commonly occurring adverse events in remifentanyl recipients (occurring in  $\geq 5\%$  of patients, not necessarily drug related) included hypotension, atrial fibrillation and vomiting. Muscle rigidity did not occur in either treatment group.

Remifentanyl was also generally well tolerated in mechanically ventilated paediatric patients in the ICU setting.

## 1. Introduction

For most patients admitted to the intensive care unit (ICU), analgesia and sedation will be required at some time throughout their hospital stay.<sup>[1]</sup> Inadequate or inappropriate use of sedation or analgesia may result in unnecessary pain, disturbed sleep and anxiety, and may potentially exacerbate confusion and delirium.<sup>[1,2]</sup>

Therefore, one of the primary challenges for clinicians in the ICU setting is to provide and maintain patient comfort. The broad spectrum of patients and conditions managed within the ICU calls for an individualised treatment approach which takes into consideration inter-individual variations and illness-induced alterations in the pharmacodynamics and pharmacokinetics of different agents.<sup>[1]</sup>

Opioids are a commonly used form of analgesia following major surgery and in patients who are critically ill.<sup>[1]</sup> Remifentanyl (Ultiva<sup>TM</sup>)<sup>1</sup> is a selective, ultra-short-acting  $\mu$ -opioid receptor agonist.<sup>[2]</sup> The efficacy and tolerability of adjunctive intrave-

nous remifentanyl in general anaesthesia has been well documented in a broad spectrum of patients undergoing surgical procedures.<sup>[3]</sup> This article reviews the efficacy of intravenous remifentanyl in patients requiring sedation and analgesia within the ICU, focusing mainly on its use in patients requiring mechanical ventilation.

## 2. Pharmacodynamic Properties

The pharmacodynamic properties of remifentanyl have been reviewed previously<sup>[3]</sup> and are summarised in table I; this section focuses on the properties of the drug most relevant to the ICU setting.

Remifentanyl is a 4-anilidopiperidine derivative of fentanyl containing an ester linkage to propanoic acid.<sup>[3]</sup> It is highly active and ultra-short acting and, consistent with its agonist activity at the  $\mu$ -receptor, displays analgesic effects (table I).<sup>[3]</sup> The primary metabolite of remifentanyl, remifentanyl acid (GR90291) [see section 3], has negligible pharmacological activity compared with the parent drug.<sup>[4-6]</sup>

**1** The use of trade names is for product identification purposes only and does not imply endorsement.

**Table I.** Overview of the *in vitro* and *in vivo* pharmacodynamic characteristics of remifentanyl (REM) in animal models, healthy volunteers, patients (pts) undergoing surgery or other procedures and intensive care unit (ICU) pts**Analgesic effects**

Similar potency to that of FEN and ≈16- to 70-fold more potent than ALF based on analgesia testing as well as on EEG and MAC reduction studies in adults<sup>[7,20,21]</sup> (reviewed by Egan<sup>[4,22]</sup>)

Competitively inhibited by the μ-receptor antagonist naloxone<sup>[23,24]</sup> but not by the κ-receptor antagonist norbinaltorphimine<sup>[23]</sup>

Analgesic efficacy in healthy volunteers using various pain models<sup>[25-28]</sup>

Rapid onset of action (≈1 min) and rapid offset of action following discontinuation of a continuous infusion (≈3–10 min)<sup>[7-9]</sup>

Offset of action not altered to a clinically significant extent by renal impairment or prolonged infusion in ICU pts.<sup>[10]</sup> Shorter median time to offset of action than with MOR or FEN at day 10 in mechanically ventilated ICU pts (15 vs 70 min;  $p < 0.001$ )<sup>[11]</sup>

**Haemodynamic effects**

Displays typically dose-dependent inhibition of HR and MAP in animal models<sup>[9,29,30]</sup>

Dose-dependent haemodynamic responses that were similar in nature to those observed with ALF, but of shorter duration, in an animal model (10–20 vs ≥60 min recovery time)<sup>[9,30]</sup>

Significant reductions ( $p < 0.001$  vs baseline) in systolic and diastolic BP and HR in healthy volunteers with bolus doses of REM 2–30μg<sup>[31]</sup>

In pts with coronary artery disease, high-dose REM 2.0 μg/kg/min significantly reduced stroke volume index, HR, MAP, myocardial blood flow and MV<sub>O</sub><sub>2</sub> (all  $p < 0.05$  vs awake state)<sup>[32]</sup>

Generally associated with an acceptable degree of haemodynamic stability (e.g. MAP and HR) in ICU pts,<sup>[10,12-15]</sup> including during procedures such as endotracheal suctioning.<sup>[16]</sup> However, associated with clinically significant reductions in heart rate and BP at infusion rates ≥0.1 μg/kg/min in a dose-ranging study in mechanically ventilated ICU pts<sup>[17]</sup> and a significantly ( $p < 0.05$ ) lower MAP than that seen with MOR in another study<sup>[18]</sup>

**Respiratory effects**

Dose-dependently decreased respiratory rate and increased ET<sub>CO</sub><sub>2</sub> in healthy volunteers (both  $p < 0.05$  vs placebo)<sup>[33]</sup>

Caused dose-dependent respiratory depression (like alfentanil); nadir occurred 2.5–5 min after a single bolus dose of REM in healthy volunteers<sup>[7,33,34]</sup>

Respiratory drive depression occurred with infusion rates of >0.05 μg/kg/min in critically ill pts<sup>[17]</sup>

Following extubation of mechanically ventilated ICU pts, fewer REM than MOR recipients had a respiratory rate of <10 breaths/min (4% vs 13%;  $p = 0.042$ )<sup>[13]</sup> and the respiratory rate was higher with REM than with MOR (14 vs 11 breaths/min;  $p = 0.03$ )<sup>[18]</sup>

**CNS effects**

Generally, no clinically relevant effect on cerebral blood flow,<sup>[35,36]</sup> cerebrovascular CO<sub>2</sub> reactivity<sup>[37-39]</sup> or cerebral capacity<sup>[40]</sup> in healthy adult volunteers<sup>[35,37,40]</sup> or surgical pts<sup>[36,38,39]</sup>

No significant differences between REM, FEN and MOR recipients in mean ICP (12.0 vs 13.9 vs 10.3mm Hg) or CPP (68.8 vs 75.6 vs 77.0mm Hg) in mechanically ventilated ICU pts with acute brain injury or who had undergone neurosurgery<sup>[14]</sup>

No significant effect on ICP, CPP or cerebral blood flow velocity in mechanically ventilated ICU pts with traumatic brain injury<sup>[15]</sup>

Increased mean ICP from baseline (from 17 to 19–22mm Hg;  $p < 0.05$ ) and decreased mean CPP (from 74 to 59–63mm Hg;  $p < 0.05$ ) in mechanically ventilated pts with severe traumatic brain injury.<sup>[19]</sup> ICP also increased to 20–22mm Hg ( $p < 0.05$  vs baseline) following endotracheal suctioning

**Interactions with hypnotic agents**

Synergistic actions when coadministered with propofol in terms of cardiorespiratory<sup>[41]</sup> and hypnotic<sup>[42]</sup> responses

**ALF** = alfentanil; **BP** = blood pressure; **CPP** = cerebral perfusion pressure; **EEG** = electroencephalogram; **ET<sub>CO</sub><sub>2</sub>** = end-tidal carbon dioxide levels; **FEN** = fentanyl; **HR** = heart rate; **ICP** = intracranial pressure; **MAC** = minimum alveolar concentration; **MAP** = mean arterial pressure; **MOR** = morphine; **MV<sub>O</sub><sub>2</sub>** = myocardial oxygen uptake.

Remifentanyl has a rapid onset of action (≈1 minute) and a rapid offset of action following discontinuation (≈3–10 minutes) [table I].<sup>[7-9]</sup> The time to offset of action was not prolonged to a clinically significant extent by renal impairment or prolonged infusion, according to the results of a study in 40 post-surgical or medical ICU patients who had normal renal function or mild renal impairment (creati-

nine clearance [CL<sub>CR</sub>] ≥3 L/h [≥50 mL/min]) versus moderate to severe renal impairment (CL<sub>CR</sub> <3 L/h [<50 mL/min]).<sup>[10]</sup> Patients received an intravenous infusion of remifentanyl (initial infusion rate 0.1–0.15 μg/kg/min, titrated to effect) for up to 72 hours. An increase, and greater variability, in time to offset was observed in patients with moderate to severe renal impairment at 24 and 72 hours; these

differences were statistically ( $p < 0.05$  vs normal renal function/mild renal impairment group) but not clinically significant. At 72 hours, the difference between the two groups in the mean time to offset was 16.5 minutes.

Remifentanyl displays a shorter duration of action following discontinuation (3–10 min) than alfentanil (5–20 min), fentanyl (20–30 min) or morphine (180–240 min) [reviewed by Mason<sup>[8]</sup>]. Moreover, in a study in mechanically ventilated ICU patients, the median time to offset of action was significantly shorter with remifentanyl than with morphine or fentanyl after 10 days' treatment (table I).<sup>[11]</sup>

The effect of remifentanyl on haemodynamics is typical of opioids (e.g. decreased blood pressure and heart rate) [table I]. In ICU patients, remifentanyl was generally associated with an acceptable degree of haemodynamic stability,<sup>[10,12–15]</sup> including during procedures such as endotracheal suctioning<sup>[16]</sup> (table I). For example, no significant differences between mechanically ventilated ICU patients receiving remifentanyl or fentanyl were reported in terms of weighted mean heart rate (88.3 vs 88.6 beats/min) or mean arterial pressure (80.9 vs 79.6 mm Hg).<sup>[12]</sup> However, remifentanyl was associated with clinically significant reductions in heart rate and blood pressure at infusion rates of  $\geq 0.1 \mu\text{g/kg/min}$  in a dose-ranging study<sup>[17]</sup> and mean arterial pressure was significantly lower with remifentanyl than with morphine in another study<sup>[18]</sup> (see section 4.1 for study design details).

In critically ill patients, respiratory drive suppression occurred at remifentanyl infusion rates of  $>0.05 \mu\text{g/kg/min}$  in a dose-ranging study<sup>[17]</sup> (table I). Among mechanically ventilated ICU patients, recovery of spontaneous respiration was significantly better with remifentanyl than with morphine following extubation<sup>[13,18]</sup> (table I).

There were no significant differences between remifentanyl, fentanyl and morphine recipients in mean intracranial pressure (ICP) or cerebral perfusion pressure in mechanically ventilated ICU patients with acute brain injury or who had undergone neurosurgery<sup>[14]</sup> (table I). In addition, remifentanyl infusion had no significant effect on ICP, cerebral

perfusion pressure or cerebral blood flow velocity in mechanically ventilated ICU patients with traumatic brain injury (table I).<sup>[15]</sup> However, compared with baseline, ICP was significantly increased and cerebral perfusion pressure was significantly reduced with remifentanyl in mechanically ventilated patients with severe traumatic brain injury in another study<sup>[19]</sup> (table I). A significant increase from baseline in ICP was also seen following endotracheal suctioning.<sup>[19]</sup>

### 3. Pharmacokinetic Properties

The pharmacokinetics of remifentanyl have been reviewed previously by Scott and Perry<sup>[3]</sup> (including data on healthy volunteers and patients undergoing surgery). This section provides a brief overview of the pharmacokinetics of the drug, as relevant to the ICU setting. Remifentanyl pharmacokinetics were assessed using arterial blood samples.

Remifentanyl is rapidly distributed throughout the body and demonstrates linear, dose-dependent, multicompartmental pharmacokinetics.<sup>[3]</sup> The drug is approximately 70% bound to plasma proteins and rapidly equalises across the blood-brain barrier.<sup>[3]</sup> Remifentanyl also crosses the placenta but no clinically relevant effects on the neonate have been reported.<sup>[43]</sup>

Remifentanyl undergoes widespread extravascular metabolism, and is rapidly metabolised via extrahepatic, nonspecific blood and tissue esterases to its main metabolite, the essentially inactive carboxylic acid metabolite remifentanyl acid.<sup>[4,44]</sup> This organ-independent elimination makes the drug particularly useful in the ICU setting given that critically ill ICU patients often have a degree of organ dysfunction.<sup>[44]</sup> Indeed, the pharmacokinetics of remifentanyl were not altered to a clinically significant extent in ICU patients with moderate to severe renal impairment ( $\text{CL}_{\text{CR}} < 3 \text{ L/h}$  [ $< 50 \text{ mL/min}$ ]) who received the drug for up to 72 hours, compared with ICU patients with normal renal function or mild renal impairment ( $\text{CL}_{\text{CR}} \geq 3 \text{ L/h}$  [ $\geq 50 \text{ mL/min}$ ]) [table II].<sup>[44]</sup> There was high interindividual variability in volume of distribution (Vd) and clearance values

**Table II.** Pharmacokinetics of remifentanyl and remifentanyl acid in intensive care unit (ICU) patients (pts). In this study, post-surgical or medical ICU pts requiring mechanical ventilation received continuous intravenous infusion of remifentanyl for up to 72h.<sup>[44]</sup> <sup>a</sup> Pts had normal renal function or varying degrees of renal impairment. Mean values are reported

|                           | Normal renal function or mild renal impairment (n = 10) | Moderate to severe renal impairment <sup>b</sup> (n = 30) |
|---------------------------|---------------------------------------------------------|-----------------------------------------------------------|
| CL <sub>CR</sub> (mL/min) | 62.9                                                    | 14.7                                                      |
| <b>Remifentanyl</b>       |                                                         |                                                           |
| CL (mL/kg/min)            | 44.3                                                    | 59.0                                                      |
| V <sub>d</sub> (L/kg)     | 0.737                                                   | 1.76                                                      |
| t <sub>1/2</sub> (min)    | 11.4                                                    | 20.5                                                      |
| <b>Remifentanyl acid</b>  |                                                         |                                                           |
| CL (mL/kg/h)              | 176                                                     | 41.4*                                                     |
| V <sub>c</sub> (L/kg)     | 0.719                                                   | 0.768                                                     |
| Q (mL/kg/h)               | 125                                                     |                                                           |
| V <sub>p</sub> (L/kg)     | 0.685                                                   |                                                           |
| t <sub>1/2</sub> (h)      | 2.48                                                    | 18.5*                                                     |
| t <sub>1/2β</sub> (h)     | 16.6                                                    |                                                           |

a Initial remifentanyl infusion rate of 0.1–0.15 µg/kg/min, titrated to effect. If required, propofol 0.5 mg/kg/h was started and titrated to effect.

b Pts were receiving no renal replacement therapy (n = 16), intermittent renal replacement therapy (n = 9) or continuous renal replacement therapy (n = 5).

CL = clearance; CL<sub>CR</sub> = creatinine CL; Q = intercompartmental clearance; t<sub>1/2</sub> = elimination half-life; t<sub>1/2β</sub> = terminal t<sub>1/2</sub>; V<sub>c</sub> = volume of the central compartment; V<sub>d</sub> = volume of distribution; V<sub>p</sub> = volume of the peripheral compartment; \* p < 0.0001 vs normal renal function/mild renal impairment.

for remifentanyl; however, there were no significant differences between groups.<sup>[44]</sup>

The majority of remifentanyl acid (≥88%) is eliminated by the kidneys<sup>[7,45]</sup> and this metabolite accumulated in ICU patients with moderate to severe renal impairment.<sup>[44]</sup> However, this accumulation is unlikely to be clinically relevant due to the low potency of remifentanyl acid versus remifentanyl. The metabolic ratio (reflecting the ratio of remifentanyl acid : remifentanyl concentrations at steady state) in patients with moderate to severe renal impairment was ≈8-fold higher than that in patients with normal renal function or mild impairment (116 vs 15.1; p < 0.0001). Mean remifentanyl acid clearance showed a linear decline which corresponded to a decline in CL<sub>CR</sub>; clearance was significantly decreased by ≈75% in patients with moder-

ate-to-severe renal impairment compared with the normal renal function/mild renal impairment group (table II).

Remifentanyl and remifentanyl acid displayed three-compartment model pharmacokinetics in patients with normal renal function or mild renal impairment, whereas a two-compartment model was adequate for most patients with moderate-to-severe renal impairment.<sup>[44]</sup>

In patients with renal failure, pharmacokinetic modelling predicted that remifentanyl acid concentrations would reach steady state after a continuous infusion of remifentanyl 0.15 µg/kg/min over 6 days; these concentrations are not likely to exceed those observed in patients with moderate-to-severe renal impairment.<sup>[44]</sup>

A significant (p < 0.05) reduction in clearance and prolongation of terminal elimination half-life (t<sub>1/2β</sub>) have been reported in patients with end-stage renal failure who had undergone haemodialysis in the past 24 hours compared with healthy controls in a non-ICU setting.<sup>[46]</sup> However, these reductions were clinically modest and could be explained by a reduction in V<sub>d</sub> shortly after haemodialysis. Moreover, the pharmacokinetics of remifentanyl were not altered to a clinically significant extent in patients with severe chronic liver disease (n = 10) compared with healthy controls (n = 10).<sup>[47]</sup>

The context-sensitive half-time (i.e. the time required for a 50% reduction in the effect site concentration after a continuous infusion designed to maintain a constant effect site concentration) is ≈3–4 minutes, irrespective of the duration of remifentanyl infusion.<sup>[7,48]</sup> Context-sensitive half-time may be a more appropriate measure of the elimination rate of remifentanyl than t<sub>1/2β</sub>.<sup>[7]</sup> By contrast, context-sensitive half-times following infusion of sufentanyl, alfentanil and fentanyl were 33.9, 58.5 and 262.5 minutes, respectively; study drugs were infused for up to 4 hours.<sup>[48]</sup>

Based on a non-steady-state population modelling analysis, the concomitant administration of intravenous remifentanyl and propofol resulted in a significant reduction in remifentanyl central V<sub>d</sub> (V<sub>c</sub>) and distribution clearance of 41% and 41%, respec-

tively ( $p < 0.05$  for both), in 20 healthy volunteers.<sup>[49]</sup> Propofol pharmacokinetics were unaffected.

### 3.1 Special Patient Populations

Age-related changes in clearance and  $V_d$  at steady state ( $V_{d_{ss}}$ ) were seen in paediatric patients ( $n = 34$ ) undergoing surgical procedures (non-ICU setting) who received a single intravenous dose of remifentanyl  $5 \mu\text{g}/\text{kg}$ .<sup>[50]</sup> Mean remifentanyl clearance was significantly ( $p < 0.05$ ) increased in patients aged 0–2 months ( $90.5 \text{ mL}/\text{min}/\text{kg}$ ) and >2 months to <2 years ( $92.1 \text{ mL}/\text{min}/\text{kg}$ ) compared with patients aged 2–18 years ( $46.5$ – $76.0 \text{ mL}/\text{min}/\text{kg}$ ). Mean  $V_{d_{ss}}$  was significantly ( $p < 0.05$ ) higher in paediatric patients aged 0–2 months ( $452.8 \text{ mL}/\text{kg}$ ) than in older patients ( $223.2$ – $307.9 \text{ mL}/\text{kg}$ ). There were no significant age-related changes in  $t_{1/2\beta}$  ( $3.4$ – $5.7 \text{ min}$ ), reflecting the inverse relationship of age with clearance.

In healthy adult volunteers,  $V_c$  and clearance showed approximate reductions of 25% and 33% from the ages of 20 to 85 years.<sup>[51]</sup> For use in general anaesthesia, the prescribing information therefore recommends that the initial remifentanyl dose be reduced by 50% in those aged >65 years.<sup>[45]</sup> However, because of the lower initial dosages, no initial dosage reduction is required in the elderly in the intensive care setting (section 7).<sup>[45]</sup>

## 4. Therapeutic Efficacy

### 4.1 Efficacy in Mechanically Ventilated Intensive Care Unit (ICU) Patients

The efficacy of intravenous remifentanyl in providing analgesia-based sedation in adults admitted to the ICU who require mechanical ventilation has been examined in early trials (section 4.1.1) and in trials comparing remifentanyl with other opioids (section 4.1.2). Trials have also examined the analgesic efficacy of remifentanyl in paediatric ICU patients requiring mechanical ventilation (section 4.1.3).

#### 4.1.1 Early Trials

The efficacy of remifentanyl in mechanically ventilated ICU patients was first evaluated in noncomparative trials ( $n = 46$ ,<sup>[52]</sup>  $n = 10$ <sup>[17]</sup> and  $n = 132$ <sup>[53]</sup>). Patients in these trials had undergone major noncardiac surgery or needed mechanical ventilation because of respiratory insufficiency,<sup>[52]</sup> were critically ill,<sup>[17]</sup> or had undergone coronary artery bypass graft (CABG) surgery.<sup>[53]</sup> Where specified, mean patient age was 63<sup>[52]</sup> or 68<sup>[17]</sup> years and patients received remifentanyl for up to 78 hours (mean duration 9.8 hours)<sup>[52]</sup> or a median 4.8 hours (postoperative infusion time).<sup>[53]</sup> One study assessed sedation using the Ramsay Sedation Scale (RSS: 1 = patient anxious and/or agitated, to 6 = no response) and the respiratory response subscore of the comfort scale (CSRR: 1 = no coughing or spontaneous respiration, to 5 = fights ventilator, coughing or choking).<sup>[17]</sup> One study is available as an abstract.<sup>[53]</sup>

Mechanically ventilated ICU patients recovered rapidly following sedation with remifentanyl, with 31 of 46 patients (67%) extubated within 15 minutes of discontinuing the drug and 40 (87%) extubated within 45 minutes.<sup>[52]</sup> Remifentanyl was commenced at an infusion rate of  $0.15 \mu\text{g}/\text{kg}/\text{min}$  and was titrated in  $0.05 \mu\text{g}/\text{kg}/\text{min}$  increments (mean infusion rate  $0.14 \mu\text{g}/\text{kg}/\text{min}$ ). Bolus midazolam 1–3mg could be administered for insufficient sedation and clonidine  $0.5 \mu\text{g}/\text{kg}/\text{h}$  could be administered for shivering or hypertension. Remifentanyl monotherapy provided adequate analgesia and sedation in 17 of 46 (37%) patients.

Low-dose remifentanyl ( $\leq 0.05 \mu\text{g}/\text{kg}/\text{min}$ ) provided effective sedation in critically ill patients receiving mechanical ventilation in pressure support mode in a dose-ranging study.<sup>[17]</sup> A remifentanyl infusion of  $0.02 \mu\text{g}/\text{kg}/\text{min}$  was initiated and increased to 0.05, 0.1, 0.15, 0.2 and  $0.25 \mu\text{g}/\text{kg}/\text{min}$  every 30 minutes. At a dosage of  $0.05 \mu\text{g}/\text{kg}/\text{min}$ , remifentanyl improved patient adaptation to mechanical ventilation and provided sedation (RSS  $\geq 2$ ;  $p < 0.05$  vs baseline) without loss of consciousness. At this dosage, the CSRR score was 3, the same as at baseline. The bispectral index (BIS; an electroencephalographic index of the level of consciousness) was significantly ( $p < 0.05$ ) reduced



from baseline with remifentanyl dosages  $\geq 0.05 \mu\text{g}/\text{kg}/\text{min}$ . However, tracheal mucosal stimulation increased BIS up to values seen in awake patients.

Remifentanyl facilitated early extubation in patients who had undergone CABG surgery in a multicentre study.<sup>[53]</sup> Recipients of remifentanyl  $1 \mu\text{g}/\text{kg}/\text{min}$  were able to obey a command a median 4 hours after the end of surgery, had adequate respiration a median 5.2 hours after the end of surgery and could be extubated a median 6.1 hours after the end of surgery. A significantly shorter mean time to ICU discharge was reported in patients eligible for early extubation than in those extubated later (18.5 vs 43.8 hours;  $p < 0.001$ ).

#### 4.1.2 Comparisons with Other Opioids

This section mainly focuses on well designed, comparative trials in  $\geq 20$  patients (results of early, smaller trials<sup>[54,55]</sup> are not discussed). Studies compared the use of remifentanyl in analgesia-based sedative regimens with that of morphine,<sup>[11,13,14,18]</sup> fentanyl,<sup>[11,12,14,56,57]</sup> or sufentanyl<sup>[58,59]</sup> in mechanically ventilated ICU patients. Studies were randomised<sup>[11-14,18,56-59]</sup> and, where specified, of double-blind<sup>[12,13,18,56,58,59]</sup> or nonblind<sup>[11,14,57]</sup> and/or multicentre<sup>[11-14,56]</sup> or single-centre<sup>[18,57,58]</sup> design.

Trials included post-surgical, trauma and/or medical patients; a study in patients with acute brain injury or who had undergone neurosurgery is discussed separately.<sup>[14]</sup> Some studies only included patients with normal renal function<sup>[12,13,18,58]</sup> or mild renal impairment.<sup>[12,13]</sup> Where specified, mean patient age was 47–63 years.<sup>[11-14,18,56,58,59]</sup>

In most studies, remifentanyl was titrated to achieve an optimal level of analgesia and midazolam<sup>[11,13,18]</sup> or propofol<sup>[12,14,57]</sup> were administered if additional sedation was required, although in two studies all patients received both remifentanyl and either propofol<sup>[58]</sup> or midazolam.<sup>[59]</sup> Some studies also used initial titration of the comparator opioid followed by the administration of midazolam<sup>[13,18]</sup> or propofol<sup>[12]</sup> if required, and in some both the comparator opioid and midazolam<sup>[11,14,57,59]</sup> or propofol<sup>[14,58]</sup> were administered. Two of these latter studies used sedative-based regimens, in which the hypnotic component was used as the main variant

for sedation.<sup>[11,14]</sup> One study compared the effect of fast-track cardiac anaesthesia with remifentanyl with that of fentanyl (both in combination with isoflurane plus propofol) on early extubation time in patients undergoing CABG surgery.<sup>[56]</sup> Details of the drug dosages used in these trials are given in tables III and IV or discussed in subsequent text.

The duration of mechanical ventilation was  $< 5$  hours following CABG surgery<sup>[56]</sup> and up to  $\approx 3$  days in most other studies.<sup>[12,13,18,57]</sup> Patients with acute brain injury or who had undergone neurosurgery were mechanically ventilated for up to 5 days<sup>[14]</sup> and in two longer-term studies, patients were mechanically ventilated for up to  $\approx 10$  days.<sup>[11,59]</sup>

Where specified, primary endpoints included the time from arriving in the ICU until the discharge criteria were fulfilled,<sup>[57]</sup> the time from the start of study drug until extubation,<sup>[11]</sup> the mean percentage time of optimal sedation,<sup>[18]</sup> the between-patient variability in the percentage time of optimal sedation<sup>[12,13]</sup> and the between-patient variability in the mean time to neurological assessment.<sup>[14]</sup>

Sedation was evaluated using the Sedation-Agitation Scale (SAS; 1 = not rousable, to 7 = dangerous agitation)<sup>[11-13,18]</sup> or the RSS.<sup>[58]</sup> Optimal sedation was defined as an SAS score of 3–4,<sup>[11]</sup> 4<sup>[12,13,18]</sup> or 1–3,<sup>[14]</sup> or an RSS score of 2–5.<sup>[58]</sup> Analgesia was evaluated according to a 6-point Pain Intensity scale (1 = no pain, to 6 = worst possible pain).<sup>[11-14,18]</sup>

One study is only available as an abstract.<sup>[57]</sup>

Remifentanyl provided effective analgesia-based sedation in mechanically ventilated patients in the ICU setting. Optimal sedation was achieved for  $\geq 78\%$  of the time with remifentanyl (table III).<sup>[11-13,18]</sup> Moreover, the duration of optimal sedation provided by remifentanyl was generally similar to that provided by fentanyl<sup>[11,12]</sup> or morphine,<sup>[11,13]</sup> although remifentanyl provided optimal sedation for a significantly longer duration than morphine in one study (primary endpoint)<sup>[18]</sup> [table III]. In two studies, there were no significant differences between remifentanyl and fentanyl<sup>[12]</sup> or morphine<sup>[13]</sup> recipients in between-patient variability for the optimal duration of sedation during the maintenance phase (primary endpoint). In one of these studies,<sup>[12]</sup> when

**Table III.** Efficacy of remifentanyl (REM) in medical and post-surgical intensive care unit (ICU) patients (pts). Results of studies comparing REM-based analgesia with other opioids in pts requiring mechanical ventilation. All study drugs were administered intravenously

| Study (design)                                   | Pt group                           | Regimen <sup>a</sup>                                                                  | No. of pts      | Optimal sedation (% h) <sup>b</sup> | Extubation time <sup>c</sup> (h) | Duration of mechanical ventilation <sup>d</sup> (h) | Time to ICU discharge <sup>e</sup> (h) | Additional sedative requirements <sup>f</sup>            |
|--------------------------------------------------|------------------------------------|---------------------------------------------------------------------------------------|-----------------|-------------------------------------|----------------------------------|-----------------------------------------------------|----------------------------------------|----------------------------------------------------------|
| <b>Comparisons with FEN</b>                      |                                    |                                                                                       |                 |                                     |                                  |                                                     |                                        |                                                          |
| Howie et al. <sup>[56]</sup><br>(r, db, mc)      | CABG                               | REM <sup>g</sup>                                                                      | 150             |                                     |                                  | 3.6                                                 | 16.8                                   |                                                          |
|                                                  |                                    | FEN <sup>g</sup>                                                                      | 154             |                                     |                                  | 3.7                                                 | 19.2                                   |                                                          |
| Matthey et al. <sup>[57]h</sup><br>(r, nb, sc)   | Cardiac surgery                    | REM 0.1–1 µg/kg/min ± PRO 0.3–1 mg/kg bolus and/or infusion 0.5–4.0 mg/kg/h           | 80 <sup>i</sup> |                                     |                                  | 20.7*                                               | 46.1 <sup>j</sup>                      |                                                          |
|                                                  |                                    | FEN 1–2 µg/kg bolus then 1–7 µg/kg/h + MID 0.03–0.2 mg/kg bolus then 0.02–0.2 mg/kg/h |                 |                                     |                                  | 24.2                                                | 62.4 <sup>i</sup>                      |                                                          |
| Muellejans et al. <sup>[12]</sup><br>(r, db, mc) | Cardiac/general surgery or medical | REM 0.15 µg/kg/min ± PRO ≤0.5 mg/kg bolus then 0.5 mg/kg/h                            | 77              | 88.3                                | 1.1                              |                                                     | 40.8                                   | Total PRO 378mg                                          |
|                                                  |                                    | FEN 1 µg/kg bolus then 1.5 µg/kg/h ± PRO ≤0.5 mg/kg bolus then 0.5 mg/kg/h            | 75              | 89.3                                | 1.3                              |                                                     | 39.5                                   | Total PRO 683mg                                          |
| <b>Comparison with FEN or MOR</b>                |                                    |                                                                                       |                 |                                     |                                  |                                                     |                                        |                                                          |
| Breen et al. <sup>[11]</sup><br>(r, nb, mc)      | Medical and surgical               | REM 0.1–0.15 µg/kg/min ± MID ≤2mg bolus                                               | 57              | 96.9                                | 0.9**                            | 94 <sup>k</sup>                                     | 187.3                                  | Total MID 125mg <sup>k</sup>                             |
|                                                  |                                    | MID infusion and/or bolus + FEN or MOR <sup>l</sup>                                   | 48              | 97.8                                | 27.5                             | 147.5 <sup>j</sup>                                  | 209.8                                  | FEN: total MID 1100mg; MOR: total MID 525mg <sup>k</sup> |
| <b>Comparisons with MOR</b>                      |                                    |                                                                                       |                 |                                     |                                  |                                                     |                                        |                                                          |
| Chinachoti et al. <sup>[13]</sup><br>(r, db)     | Cardiac/general surgery or medical | REM 0.15 µg/kg/min ± MID 0.03 mg/kg/h                                                 | 74              | 82.7                                | 1.5                              |                                                     |                                        | Total MID 15mg                                           |
|                                                  |                                    | MOR 0.045 mg/kg/h ± MID 0.03 mg/kg/h                                                  | 78              | 84.3                                | 2.5                              |                                                     |                                        | Total MID 28.4mg                                         |
| Dahaba et al. <sup>[16]</sup><br>(r, db, sc)     | Orthopaedic or general surgery     | REM 0.15 µg/kg/min ± MID 0.03 mg/kg bolus then 0.03 µg/kg/h                           | 20              | 78.3 <sup>j</sup>                   | 0.3*                             | 14.1*                                               | 20.7*                                  | MID 0.2 µg/kg/min*                                       |
|                                                  |                                    | MOR 0.045 mg/kg/h ± MID 0.03 mg/kg bolus then 0.03 mg/kg/h                            | 20              | 66.5 <sup>j</sup>                   | 1.22                             | 18.1                                                | 41.7                                   | MID 0.5 µg/kg/min                                        |
| <b>Comparison with SUF</b>                       |                                    |                                                                                       |                 |                                     |                                  |                                                     |                                        |                                                          |
| Baillard et al. <sup>[59]</sup><br>(r, db)       | Critically ill                     | REM ≈0.17 µg/kg/min + MID 0.1 mg/kg/h                                                 | 21              |                                     | 22*                              | 144                                                 | 168                                    | Total MID 14.5 mg/kg                                     |
|                                                  |                                    | SUF 0.125 µg/kg/h + MID 0.1 mg/kg/h                                                   | 20              |                                     | 96                               | 144                                                 | 252                                    | Total MID 8.9 mg/kg                                      |

*Continued next page*

**Table III.** Contd

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| a | Study drugs were titrated to effect. <sup>[11,13,16,57,59]</sup> In most studies, PRO <sup>[12,57]</sup> or MID <sup>[11,13,18]</sup> were added to REM only if required.                                                                                                                                                                                                                                                                                                                                                                                                  |
| b | Percentage of hours on study drug during which an SAS score of 3–4 <sup>[11]</sup> or 4 <sup>[12,13,18]</sup> was maintained.                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| c | Defined as the time from discontinuation of study drug until extubation, <sup>[16,59]</sup> the time from the start of the extubation process until extubation <sup>[12,13]</sup> or the time from the start of weaning until extubation. <sup>[11]</sup> Values are means, <sup>[13,16]</sup> medians <sup>[12,59]</sup> or the 75th centile. <sup>[11]</sup>                                                                                                                                                                                                             |
| d | Defined as the time from entry to the ICU to extubation, <sup>[56,57]</sup> the time from initiation of study drug until extubation, <sup>[11]</sup> or the time from the start of study drug infusion until its discontinuation. <sup>[16,59]</sup> Values are means, <sup>[16,57]</sup> medians <sup>[56,59]</sup> or the 75th centile. <sup>[11]</sup>                                                                                                                                                                                                                  |
| e | Where specified, defined as the time from ICU arrival until discharge criteria were fulfilled, <sup>[57]</sup> the time from the start of study drug until ICU discharge, <sup>[11,12]</sup> the time from interruption of sedation until ICU discharge <sup>[59]</sup> or the time from extubation until ICU discharge. <sup>[16]</sup> Values are means, <sup>[16,57]</sup> medians <sup>[12,56,59]</sup> or the 75th centile. <sup>[11]</sup>                                                                                                                           |
| f | Means <sup>[11,18]</sup> or medians. <sup>[12,13,59]</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| g | Pts received fast-track cardiac anaesthesia with a REM bolus of 1 µg/kg and infusion of 1 µg/kg/min or a FEN bolus of 10 µg/kg and placebo infusion; further boluses were given and the REM infusion adjusted as required. ISO was used for maintenance anaesthesia and discontinued just after rewarmed, when PRO 2 mg/kg/h was commenced. On ICU admission, the PRO infusion was reduced to 0.5 mg/kg/h and adjusted as needed. 30 minutes after starting the extubation sequence, a bolus of FEN 2 µg/kg was given to REM recipients and FEN 1 µg/kg to FEN recipients. |
| h | Abstract.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| i | Total number of pts. Number in each group not specified.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| j | Primary endpoint.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| k | Values estimated from graph.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| l | All pts received MID with either FEN or MOR. Mean infusion rates were 3.0 µg/kg/h for FEN and 0.042 mg/kg/h for MOR. CABG = coronary artery bypass graft; <b>db</b> = double-blind; <b>FEN</b> = fentanyl; <b>ISO</b> = isoflurane; <b>mc</b> = multicentre; <b>MID</b> = midazolam; <b>MOR</b> = morphine; <b>nb</b> = nonblind; <b>PRO</b> = propofol; <b>r</b> = randomised; <b>SAS</b> = Sedation-Agitation Scale; <b>sc</b> = single-centre; <b>SUF</b> = sufentanil; * <i>p</i> < 0.05, ** <i>p</i> < 0.001 vs comparator.                                           |

a remifentanyl recipient who did not achieve an SAS score of 4 (deemed unrelated to the study drug) was excluded from the analysis, there was significantly less variability with remifentanyl than with fentanyl (*p* = 0.009).

The percentage of hours during which patients had no or mild pain (i.e. a Pain Intensity score of 1 or 2) was similar with remifentanyl and morphine (94.5% vs 93.9%<sup>[13]</sup> and 95.6% vs 92.6%<sup>[18]</sup>). Patients had at least moderate pain for a mean 2.6% and 3.1% of the maintenance phase with remifentanyl and fentanyl.<sup>[12]</sup> However, compared with fentanyl recipients, remifentanyl recipients experienced at least moderate pain for significantly greater proportions of the extubation (1.4% vs 6.5%; *p* = 0.013), post-extubation (3.6% vs 10.2%; *p* = 0.001) and post-treatment (5.1% vs 13.5%; *p* = 0.001) periods, probably reflecting the rapid offset of action of remifentanyl.<sup>[12]</sup>

The need for additional sedation generally appeared greater with fentanyl and morphine regimens than with remifentanyl, although statistical analysis of this parameter was provided for only one trial<sup>[18]</sup> (table III).<sup>[11-13,18]</sup> A propofol infusion was added to remifentanyl or fentanyl in 35% and 40% of patients<sup>[12]</sup> and midazolam was added to remifentanyl or morphine in 22% and 27%<sup>[13]</sup> and 30% and 45%<sup>[18]</sup> of patients. In addition, midazolam was not required by 26% of remifentanyl recipients in the longer-term study.<sup>[11]</sup>

Midazolam requirements appeared greater in remifentanyl than sufentanil recipients in one study, although statistical analysis was not reported (table III).<sup>[59]</sup> In addition, remifentanyl ≈0.18 µg/kg/min plus propofol 2.1 mg/kg/h and sufentanil 0.5 µg/kg/h plus propofol 1.3 mg/kg/h (mean dosages) provided effective sedation and analgesia (median RSS of 3) in 20 mechanically ventilated patients admitted to the ICU following either surgery or trauma in a randomised, double-blind trial; the propofol dosage was significantly higher in remifentanyl than in sufentanil recipients (*p* = 0.012).<sup>[58]</sup> However, remifentanyl was associated with a more rapid recovery from sedation than sufentanil; within 10 min-

**Table IV.** Efficacy of remifentanyl (REM)-based analgesia in patients (pts) with acute brain injury<sup>[14]</sup> or who had undergone neurosurgery<sup>[14,60]</sup> and were being mechanically ventilated in the intensive care unit (ICU). Results of a randomised, nonblind, multicentre trial<sup>[14]</sup> and a retrospective analysis.<sup>[60]</sup> All study drugs were administered intravenously

| Study                            | Regimen <sup>a</sup>                                                               | No. of pts | Optimal sedation (% h) <sup>b</sup> | Between-pt variability in mean time to neurological assessment | Mean time to neurological assessment (h) | Time to extubation <sup>c</sup> (h; median <sup>[14]</sup> or mean <sup>[60]</sup> ) | Median duration of mechanical ventilation (h) | Time to ICU discharge <sup>d</sup> (h; median <sup>[14]</sup> or mean <sup>[60]</sup> ) | Additional sedative requirements (median) [mg/kg/h] |
|----------------------------------|------------------------------------------------------------------------------------|------------|-------------------------------------|----------------------------------------------------------------|------------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------|
| Karabinis et al. <sup>[14]</sup> | REM 0.15 µg/kg/min ± PRO <sup>e</sup> ≤0.5 mg/kg bolus and/or 0.5 mg/kg/h infusion | 87         | 95.6                                | 0.44*††                                                        | 0.41***††                                | 1.0††                                                                                | 24.8                                          | 43.5                                                                                    | PRO 1.93; MID 0.18                                  |
|                                  | PRO <sup>e</sup> + FEN                                                             | 34         | 98.1‡                               | 0.86 <sup>f</sup>                                              | 0.71                                     | 0.7                                                                                  | 24.1                                          | 42.9                                                                                    | PRO 2.49; MID 0.11                                  |
|                                  | PRO <sup>e</sup> + MOR                                                             | 40         | 99.0‡                               | 0.98 <sup>f</sup>                                              | 0.82                                     | 1.9                                                                                  | 37.0                                          | 49.6                                                                                    | PRO 2.30; MID 0.13                                  |
| Wilhelm et al. <sup>[60] g</sup> | REM 0.1–0.2 µg/kg/min + PRO 0.5–3 mg/kg/h                                          | 30         |                                     |                                                                |                                          | 0.8*                                                                                 |                                               | 43.2*                                                                                   |                                                     |
|                                  | FEN 0.03–0.2 mg/h + MID 2–12 mg/h                                                  | 30         |                                     |                                                                |                                          | 8.0                                                                                  |                                               | 86.4                                                                                    |                                                     |

a Study drugs were titrated to effect.<sup>[14,60]</sup> Starting dosages of study drugs in the FEN and MOR treatment arms were not specified in one study.<sup>[14]</sup>

b Median percentage of hours on study drug during which a Sedation-Agitation Scale score of 1–3<sup>[14]</sup> was maintained.

c Defined as the time from the start of the extubation process until extubation<sup>[14]</sup> or not specified.<sup>[60]</sup>

d Defined as the time from the start of extubation until ICU discharge<sup>[14]</sup> or not specified.<sup>[60]</sup>

e PRO was replaced by MID in pts requiring sedation for >3d.

f Primary endpoint.

g Abstract.

**FEN** = fentanyl; **MID** = midazolam; **MOR** = morphine; **PRO** = propofol; \* p < 0.05, \*\* p = 0.001 vs FEN; † p < 0.01, †† p ≤ 0.001 vs MOR; ‡ p < 0.001 vs REM.

utes of cessation of the opioid infusion, RSS scores were 1.5 versus 3 ( $p = 0.015$ ).

Remifentanyl was at least as effective as fentanyl, morphine and sufentanil in terms of recovery parameters (table III). In some studies, including a study<sup>[11]</sup> examining longer-term mechanical ventilation, remifentanyl was associated with a significantly shorter duration of mechanical ventilation than fentanyl<sup>[11,57]</sup> or morphine<sup>[11,18]</sup> (primary endpoint in one study<sup>[11]</sup>) [table III]. Definitions for the duration of mechanical ventilation varied between studies (see table III for definitions).

In addition, the extubation time was generally <3 hours in remifentanyl recipients<sup>[11-13,18]</sup> and was significantly shorter with remifentanyl than with fentanyl,<sup>[11]</sup> morphine<sup>[11,18]</sup> or sufentanil<sup>[59]</sup> (table III). Remifentanyl was also associated with a shorter time to ICU discharge than fentanyl<sup>[57]</sup> or morphine<sup>[18]</sup> in some studies (table III).

Both remifentanyl- and fentanyl-based regimens allowed early extubation in patients who had undergone CABG surgery.<sup>[56]</sup> The median time from ICU admission until extubation was  $\approx 3.5$  hours and the median duration of ICU stay was <1 day (table III). A limitation of this study was that an infusion of remifentanyl was compared with bolus doses of fentanyl; a *post hoc* analysis suggested that the dosing regimens were not equipotent.<sup>[56]</sup>

Two studies noted an absence of tolerance to remifentanyl.<sup>[11,18]</sup> In a shorter-term study, mean remifentanyl infusion rates were 0.14  $\mu\text{g}/\text{kg}/\text{min}$  in the first hour of infusion and 0.11  $\mu\text{g}/\text{kg}/\text{min}$  at the start of weaning<sup>[18]</sup> and in a longer-term study, the mean remifentanyl infusion rate increased slightly up to day 3 and then was constant until day 10.<sup>[11]</sup> However, in another longer-term study, tolerance was seen in 6 of 21 (29%) remifentanyl recipients after a median duration of sedation of 8.5 days.<sup>[59]</sup>

#### In ICU Patients with Brain Injuries

Remifentanyl was associated with rapid and predictable emergence from sedation in mechanically ventilated ICU patients with acute brain injury or who had undergone neurosurgery, and was superior to fentanyl or morphine in this regard in a nonblind study.<sup>[14]</sup> Significantly less between-patient variability

in the time to neurological assessment occurred in patients receiving analgesia-based sedation with remifentanyl than in those receiving hypnotic-based sedation incorporating fentanyl or morphine (primary endpoint) [table IV]. In addition, the mean time to neurological assessment was significantly shorter with remifentanyl than with fentanyl or morphine (table IV). The proportion of ICU staff rating the ability of the study drug to wake patients for neurological assessment as good or excellent was 78% for remifentanyl, 25% for fentanyl and 8% for morphine.

The percentage of time on study drug with optimal sedation (defined as an SAS score of 1–3) was significantly lower with remifentanyl than with fentanyl or morphine, although optimal sedation was maintained for >95% of the time in all three treatment groups (table IV). Across all three treatment arms, patients reported no or mild pain for >99% of the treatment period; >90% of patients in each treatment arm received propofol and  $\geq 30\%$  received midazolam.

Remifentanyl recipients were extubated significantly earlier than patients receiving morphine (table IV).<sup>[14]</sup> However, there were no significant between-treatment differences in the duration of mechanical ventilation or time to ICU discharge (table IV). Results concerning the effect of remifentanyl on ICP and cerebral perfusion pressure are discussed in section 2.

The extubation time and time until ICU discharge were significantly shorter with remifentanyl plus propofol than with fentanyl plus midazolam in mechanically ventilated ICU patients who had undergone supratentorial brain surgery, according to the results of a retrospective analysis (table III).<sup>[60]</sup> The results of this study should be interpreted with caution given its retrospective design and the fact that it is only available as an abstract.

#### 4.1.3 In Paediatric Patients

The analgesic efficacy of remifentanyl in paediatric ICU patients requiring mechanical ventilation has been examined in two trials.<sup>[61,62]</sup> A randomised, double-blind study included 22 patients (mean age 13 years; range 3–16 years) undergoing orthopaedic

spinal surgery.<sup>[61]</sup> Patients received intravenous remifentanyl 0.1 µg/kg/min or fentanyl 1.5 µg/kg/h, titrated to effect. If adequate sedation was not achieved, propofol 0.3 mg/kg/h was started and titrated to effect. The efficacy of remifentanyl was also examined in 18 newborns requiring mechanical ventilation in a noncomparative study; newborns received remifentanyl 0.25 µg/kg/min, titrated to effect (mean infusion rate 0.15 µg/kg/min; mean infusion time 66.9 hours).<sup>[62]</sup>

Remifentanyl provided similar analgesia-based sedation to fentanyl in paediatric patients who were being mechanically ventilated postoperatively.<sup>[61]</sup> The median duration of the ICU stay was 3 days in remifentanyl recipients and 2 days in fentanyl recipients and the median duration of mechanical ventilation was 19 and 18.5 hours in the corresponding treatment groups. There were no significant differences between remifentanyl and fentanyl recipients in the time in which a behavioural pain scale score of 3 was achieved (5 vs 10 minutes) or the time from the end of infusion to extubation (5 vs 10 minutes). Propofol was administered to three remifentanyl recipients and one fentanyl recipient (total propofol dose 11.5 vs 20mg).

In newborns, optimal analgesia was achieved with remifentanyl in a mean 20 hours.<sup>[62]</sup> Following discontinuation of remifentanyl, extubation occurred in a mean 18 minutes.

#### 4.2 Efficacy During Other Painful Procedures in ICU Patients

Several studies have examined the efficacy of remifentanyl in ICU patients undergoing painful procedures such as dressing changes<sup>[63]</sup> or endotracheal suctioning.<sup>[16,19,64]</sup>

Remifentanyl provided adequate analgesia in ICU patients with severe burns (n = 31) during dressing changes, according to the results of a noncomparative study.<sup>[63]</sup> Over a 4-month period, patients received intravenous remifentanyl 0.1–5 mg/h (mean 0.5 mg/h) in combination with midazolam, ketamine or propofol; the study included both intubated and nonintubated patients. The mean dosage necessary for the provision of analgesia was 0.3 mg/h in nonin-

tubated patients and 0.88 mg/h in intubated patients. The overall mean cumulative dosage was 11.96 mg/day reaching a maximum of 153 mg/day. The basal dose of remifentanyl was increased by ≈30% approximately 10 minutes prior to the inspection, cleaning and dressing of wounds.

An intravenous infusion of remifentanyl effectively reduced stress during endotracheal suctioning in mechanically ventilated post-surgical ICU patients (n = 16) sedated with sufentanyl, according to the results of a saline-controlled study (available as an abstract).<sup>[16]</sup> Sufentanyl 15–150 µg/h was administered to maintain background sedation levels at RSS scores of 2–3. Prior to endotracheal suctioning, patients randomly received remifentanyl 1 µg/kg or saline. For patients receiving remifentanyl, the BIS index and systemic haemodynamic variables did not change in response to stimulation. Patients receiving a saline infusion displayed significant increases in heart rate and systolic blood pressure (indicating a stress response) compared with those administered remifentanyl (p < 0.05).<sup>[16]</sup> RSS scores and responses to verbal commands were similar before and after administration of remifentanyl or saline.<sup>[16]</sup>

The cough reflex was suppressed by remifentanyl in a dose-dependent manner during endotracheal suctioning in mechanically ventilated patients with severe traumatic brain injury (n = 20). Patients received intravenous boluses of remifentanyl 1, 2 or 4 µg/kg in a stepwise manner, followed by infusions of 0.25, 0.5 or 1 µg/kg/min, respectively.<sup>[19]</sup> With the corresponding treatment regimens, cough reflex was absent in 4 of 20 (20%), 5 of 20 (25%) and 15 of 20 (75%) patients. The effect of remifentanyl on ICP and cerebral perfusion pressure is discussed in section 2.

Procedures such as endotracheal suctioning, postural drainage and bronchoscopy could be performed without any corresponding increase in ICP or decreases in mean arterial or cerebral perfusion pressures, according to case report data from six patients admitted to the ICU with either spontaneous intracranial bleeding (two cases of subarachnoid haemorrhage and one case of intraventricular haemorrhage) or severe traumatic subdural haemor-

rhage (two patients were not intubated).<sup>[64]</sup> These patients received remifentanyl administered as a bolus 0.05–1 µg/kg then a continuous infusion of 0.03–0.26 µg/kg/min titrated to effect.

## 5. Tolerability

### 5.1 In Adult Patients

Tolerability data were obtained from the trials in adult ICU patients receiving mechanical ventilation discussed in section 4.1.<sup>[11–14,18,56]</sup>

Remifentanyl was generally well tolerated in ICU patients requiring mechanical ventilation.<sup>[11–14,18,56]</sup> The most commonly occurring adverse events in remifentanyl recipients were related to its µ-opioid agonist properties (e.g. bradycardia, hypotension).<sup>[12,13]</sup>


The tolerability of remifentanyl was generally similar to that of fentanyl or morphine in ICU patients requiring short-term mechanical ventilation for up to ≈3 days.<sup>[12,13,18]</sup> In terms of the proportion of patients experiencing drug-related adverse events, there was no significant difference between remifentanyl and morphine recipients (22% vs 16%),<sup>[13]</sup> or between remifentanyl and fentanyl recipients (23% vs 17%).<sup>[12]</sup> Moreover, there was no significant difference between remifentanyl and fentanyl recipients in the incidence of hypotension (10% vs 9%), nausea (9% vs 6%), fever (5% vs 9%) or vomiting (5% vs 6%).<sup>[12]</sup> A serious adverse event (hypotension) that was possibly related to the study drug was reported in a remifentanyl recipient in one study.<sup>[13]</sup>

In patients who required mechanical ventilation following CABG surgery, the incidence of hypotension during the ICU stay was significantly higher in remifentanyl than in fentanyl recipients (21% vs 6.5%;  $p < 0.05$ ).<sup>[56]</sup> There was no significant between-group difference in the incidence of bradycardia.

In patients being mechanically ventilated in the ICU following acute brain injury or neurosurgery, drug-related adverse events were reported in 25% of remifentanyl recipients, 8% of fentanyl recipients and 10% of morphine recipients.<sup>[14]</sup> There were no

significant differences between remifentanyl and fentanyl or morphine recipients in the incidence of hypotension (14% vs 11% and 5%), bradycardia (6% vs 5% or 5%) or polyuria (4% vs 5% and 0%). One remifentanyl recipient experienced a serious drug-related adverse event (bradycardia).

In critically ill patients mechanically ventilated for up to 10 days, drug-related adverse events occurred in 11% of remifentanyl recipients (74% of whom also received midazolam) and in 8% of patients receiving a comparator regimen (midazolam with fentanyl or morphine).<sup>[11]</sup> The most commonly occurring adverse events in remifentanyl recipients (occurring in ≥5% of patients, not necessarily drug related) included hypotension, atrial fibrillation and vomiting (figure 1). One patient receiving fentanyl and midazolam experienced serious treatment-related hypotension which was considered to be life-threatening. Muscle rigidity did not occur in either treatment group. Mortality was 13% in remifentanyl recipients and 10% in recipients of the comparator regimen. Liver function tests and creatinine clearance remained stable throughout the treatment period.<sup>[11]</sup>



**Fig. 1.** Tolerability of remifentanyl-based regimen in critically ill patients admitted to the intensive care unit requiring mechanical ventilation. Adverse events occurring with an incidence of ≥5% in patients mechanically ventilated for up to 10 days. Patients received remifentanyl (0.1–0.15 µg/kg/min) plus boluses of midazolam ≤2mg if required (n = 57) or a comparator regimen comprising midazolam administered by bolus and/or infusion alone (n = 11) or in combination with fentanyl (n = 30) or morphine (n = 7).<sup>[11]</sup> Study drugs were titrated to effect.

## 5.2 In Paediatric Patients

Data concerning the tolerability of remifentanyl in paediatric patients being mechanically ventilated in the ICU were obtained from the study discussed in section 4.1.3.<sup>[61]</sup> Remifentanyl was generally well tolerated in this patient group. There were no significant differences between remifentanyl and fentanyl recipients in terms of clinical adverse events. Nausea occurred in 8 of 11 remifentanyl and 6 of 11 fentanyl recipients and vomiting was reported in 6 of 11 remifentanyl and 5 of 11 fentanyl recipients. Chest wall rigidity did not occur in any patient.

## 6. Pharmacoeconomic Considerations

Infusion of remifentanyl plus propofol was associated with significantly lower staff costs than fentanyl plus midazolam, according to the results of a prospective cost-consequence analysis (not yet fully published).<sup>[65]</sup> The study was conducted in a German ICU unit and involved patients who were being mechanically ventilated following cardiac surgery. The cost analysis was conducted from a hospital perspective and considered only direct costs (including drug costs, staff costs and the costs of materials). Details of the drug regimens used are discussed in section 4.1.2.<sup>[57]</sup> Nursing costs were significantly lower with remifentanyl than with fentanyl (€869 vs €1131;  $p < 0.05$ ), as were physician costs (€260 vs €352;  $p < 0.05$ ) [2003 prices]. However, the cost of study drugs was significantly higher with remifentanyl than with fentanyl (€353 vs €42;  $p < 0.05$ ), and there was no significant difference between remifentanyl and fentanyl in total costs (€1712 vs €1729).

Scenario analysis showed that a lower remifentanyl infusion rate combined with a higher propofol infusion rate (corresponding to routine practice) would have rendered total cost savings compared with fentanyl plus midazolam. Univariate sensitivity analysis revealed that the pharmacoeconomic results were sensitive to changes in drug and nursing costs.<sup>[65]</sup>

The remifentanyl regimen was also associated with clinical benefits, including a significantly shorter duration of mechanical ventilation and time

in the ICU,<sup>[57]</sup> as also found in other studies<sup>[11,18]</sup> (see section 4.1.2). Although not investigated in this cost-consequence analysis,<sup>[65]</sup> a reduction in mechanical ventilation duration decreases the risk of ventilator-associated morbidity, such as pneumonia,<sup>[66]</sup> and associated costs.<sup>[67,68]</sup>

## 7. Dosage and Administration

In the EU, remifentanyl is indicated to provide analgesia and sedation in mechanically ventilated ICU patients aged  $\geq 18$  years.<sup>[45]</sup>

Remifentanyl may initially be administered alone to mechanically ventilated ICU patients.<sup>[45]</sup> Bolus injection of remifentanyl is not recommended in the ICU setting. Rather, an intravenous infusion rate of 0.1–0.15  $\mu\text{g}/\text{kg}/\text{min}$  (6–9  $\mu\text{g}/\text{kg}/\text{h}$ ) should initially be used and the dosages should subsequently be titrated in 0.025  $\mu\text{g}/\text{kg}/\text{min}$  (1.5  $\mu\text{g}/\text{kg}/\text{h}$ ) increments (at intervals of  $\geq 5$  minutes) to achieve the required level of analgesia and sedation.

If sedation is not adequate at a remifentanyl infusion rate of 0.2  $\mu\text{g}/\text{kg}/\text{min}$  (12  $\mu\text{g}/\text{kg}/\text{h}$ ), it is recommended that an appropriate sedative agent (e.g. propofol or midazolam) be initiated and the dosage titrated to the desired level of sedation.<sup>[45]</sup> The use of remifentanyl will reduce the dosage requirement of concomitantly administered sedative agents in adult ICU patients. Typical initial bolus doses and infusion rates are  $\leq 0.5$  mg/kg and 0.5 mg/kg/h for concomitant propofol, and  $\leq 0.03$  mg/kg and 0.03 mg/kg/h for concomitant midazolam. The remifentanyl infusion rate can be further increased in increments of 0.025  $\mu\text{g}/\text{kg}/\text{min}$  (1.5  $\mu\text{g}/\text{kg}/\text{h}$ ) if additional analgesia is needed. No adjustments to the above-mentioned dosages are necessary in patients with renal impairment, including those undergoing renal replacement therapy. In addition, no initial dose reduction is required in elderly patients aged  $> 65$  years who are receiving remifentanyl in the intensive care setting.

The remifentanyl infusion rate can be increased  $\geq 5$  minutes before a stimulating and/or painful procedure to provide additional analgesia.<sup>[45]</sup>

Prior to extubation, the remifentanyl infusion rate should be gradually titrated down to 0.1  $\mu\text{g}/\text{kg}/\text{min}$



(6 µg/kg/h).<sup>[45]</sup> After extubation, the remifentanyl infusion rate should be further decreased in 25% decrements at intervals of at least 10 minutes until the infusion is discontinued. Only down-titration should occur during weaning from ventilation. Transition to alternative analgesic and sedative drugs should be planned and initiated prior to discontinuation of remifentanyl.

Formal dosage recommendations for the use of remifentanyl in paediatric patients in the ICU setting are not available.

For further details regarding the use of remifentanyl in special patient populations, and contraindications and precautions governing its use, the manufacturer's prescribing information should be consulted.

## 8. Place of Remifentanyl When Used for Analgesia and Sedation in the ICU

Sedation and analgesia are core components of effective patient management in the ICU setting.<sup>[69]</sup> A combination of analgesia and sedation is necessary to relieve pain, agitation and anxiety, and to help adaptation to and compliance with procedures such as endotracheal intubation and mechanical ventilation.<sup>[69]</sup> Additional benefits of providing optimal sedation and analgesia in critically ill patients include ensuring adequate sleep and possibly reducing morbidity.<sup>[69]</sup> There is also the potential for cost savings associated with reduced ICU and hospital stays, which ultimately lead to more efficient use of resources.<sup>[2]</sup>

Within the ICU, the majority of patients receive an opioid to provide analgesia and a hypnotic agent such as midazolam or propofol for sedation.<sup>[12,70]</sup> Historically, these agents have often been administered using a sedative-based regimen which minimises the opioid dose while manipulating the sedative dose to provide optimal patient comfort.<sup>[11,14,71]</sup> This regimen is effective when traditional opioids are administered, since it minimises the potential for drug accumulation and the unpredictable recovery or weaning from mechanical ventilation associated with some of these agents.<sup>[11]</sup> Even though newer synthetic opioids such as fentanyl,

sufentanyl and alfentanil have shorter durations of action than morphine (reflecting rapid redistribution), they still have relatively long half-lives ( $\approx 70$ – $90$  min for alfentanil and  $\approx 120$ – $480$  min for fentanyl and sufentanyl), leading to accumulation and a prolonged duration of action with repeat bolus injection or infusion.<sup>[23]</sup> Moreover, these agents are eliminated via hepatic metabolism, with the potential for prolonged retention in patients with hepatic impairment.<sup>[23,71]</sup> The hypnotic component of sedative-based regimens may also be associated with problems. For example, the metabolism of midazolam may be unpredictable when the drug is administered by continuous infusion to critically ill patients.<sup>[2]</sup> Sedative-based regimens may also be associated with oversedation and its attendant complications (e.g. hypotension, increased time on the ventilator and in the ICU).<sup>[72]</sup>

An alternative to sedative-based regimens is analgesia-based sedative regimens (analgo-sedation) which provide pain relief with an opioid first and then a sedative agent is administered if and when required.<sup>[11,12]</sup> While this strategy may enhance patient comfort, concerns regarding opioid accumulation have, to date, limited its use.

Recent guidelines concerning the use of analgesics and sedatives in ICU patients state that the pain should be treated prior to the sedation of an agitated, critically ill patient.<sup>[69]</sup> When deciding on the most appropriate agent, consideration needs to be given to the patient's underlying medical condition, expected duration of sedation and the ease of administering a particular agent.<sup>[1]</sup> Drug choice is further complicated in critically ill patients who may have a systemic illness, multiple organ failure and haemodynamic instability.<sup>[73]</sup> Agents that can offer a clearly defined and predictable onset and offset of action, and that do not show any evidence of accumulation, are likely to be treatments of choice in the ICU setting.<sup>[73,74]</sup>

Remifentanyl possesses a number of properties that support its use in the ICU setting.<sup>[1,74]</sup> It specifically targets the  $\mu$ -opioid receptors that mediate pain and has a highly predictable onset and offset of action (section 2), allowing it to be easily titrated to

achieve effective analgesia.<sup>[2,11]</sup> In addition, remifentanyl has a context-sensitive half-time of approximately 3–4 minutes irrespective of the duration of infusion (section 3).<sup>[74]</sup> Remifentanyl does not accumulate and its organ-independent metabolism is not affected by renal or hepatic impairment; the accumulation associated with its metabolite, remifentanyl acid, in renal impairment is not considered clinically significant (section 3).<sup>[1,2,44,74]</sup>

In addition to providing effective pain relief and sedation, remifentanyl enhances patient comfort and allows fast and predictable extubation when administered to critically ill ICU patients requiring short-term mechanical ventilation (section 4.1). Remifentanyl-based analgesia was also associated with sedative-sparing effects, with the majority of remifentanyl recipients not requiring additional propofol or midazolam.<sup>[12,13,18]</sup> Shorter durations of mechanical ventilation and quicker ICU discharge times were seen with remifentanyl than with comparator opioids in two shorter-term studies.<sup>[18,57]</sup> These findings were confirmed in longer-term studies; remifentanyl was associated with a shorter weaning time than fentanyl, morphine or sufentanil in two studies<sup>[11,59]</sup> and a shorter duration of mechanical ventilation than fentanyl or morphine in one study.<sup>[11]</sup> A shorter duration of mechanical ventilation may help minimise the risk of complications (e.g. pneumonia, airway trauma) and reduce costs.<sup>[75]</sup> One of these longer-term studies also showed no evidence of remifentanyl accumulation over time.<sup>[11]</sup>

The fact that remifentanyl can be easily and rapidly titrated to effect may make it easier to maintain optimal levels of analgesia and sedation.<sup>[12]</sup> Moreover, it has been suggested that the rapid offset of action of remifentanyl means that patient monitoring need not be as intensive as with fentanyl; if a patient becomes oversedated, this should be easily rectified by altering the infusion rate.<sup>[12]</sup> A drawback of its rapid offset of action is that patients may experience pain following discontinuation of remifentanyl.<sup>[12]</sup> This highlights the need to consider analgesic requirements prior to discontinuing remifentanyl, in

order to ensure a smooth transition to alternative analgesia.<sup>[12,72]</sup>

In patients with neurological impairment, it is imperative that physicians are able to quickly assess neurological function and, therefore, rapid and predictable emergence from sedation is crucial.<sup>[14,74]</sup> Clinical trial data indicate that remifentanyl-based analgesia allowed earlier neurological assessment than either fentanyl or morphine (administered in a hypnotic-based regimen; section 4.1). This suggests that remifentanyl provides better sedation control and has greater predictability of the offset of effect.<sup>[14]</sup> In this study, remifentanyl and fentanyl and morphine provided optimal sedation for >95% of the treatment period.

Remifentanyl also appears to have potential in paediatric ICU patients requiring mechanical ventilation, as it had similar efficacy to fentanyl in post-operative paediatric patients in one small study (section 4.1.3). Remifentanyl may have a particularly important role to play in paediatric patients given concerns over propofol infusion syndrome, which has been observed in critically ill children receiving long-term, high-dose propofol infusion.<sup>[76,77]</sup> More data concerning the use of remifentanyl in this patient population are needed.

In addition to its use as an analgesic and sedative in mechanically ventilated ICU patients, remifentanyl has also demonstrated efficacy in providing relief during painful procedures such as wound dressing in patients with severe burns or endotracheal suctioning in mechanically ventilated patients (section 4.2).

Remifentanyl is generally well tolerated in a range of ICU patients requiring mechanical ventilation, including post-surgical and medical patients. A similar type and frequency of treatment-related adverse events were reported with remifentanyl, fentanyl and morphine regimens (section 5). Remifentanyl was generally considered to be associated with an acceptable degree of haemodynamic stability (section 2).

It would be of interest to have more data concerning the use of remifentanyl in specific patient groups. For example, only one<sup>[59]</sup> of the trials discussed in

section 4.1.2 specifically noted the inclusion of patients with septic shock. Patients with septic shock are hypotensive and are usually receiving vasopressors,<sup>[78]</sup> and the use of analgesics and sedatives in such patients may aggravate hypotension.<sup>[79]</sup> Use of a shorter-acting agent such as remifentanyl may be preferable as it allows for fast discontinuation in the event of poor haemodynamic tolerance. The rapid onset, easy titratability and lack of accumulation associated with remifentanyl are important attributes in this patient group.<sup>[79]</sup>

Preliminary results of a cost-consequence analysis suggest that use of remifentanyl in mechanically ventilated patients may be associated with savings in staff costs (section 6).<sup>[65]</sup> A reduction in the length of ICU and hospital stay may also yield savings, as well as decreasing the risk of costly complications, which may help to balance the high drug costs. Further economic evaluation is needed to corroborate these preliminary findings.

In conclusion, analgesia-based sedation with remifentanyl is a useful option for mechanically ventilated patients in the ICU setting. Its unique properties (e.g. organ-independent metabolism, lack of accumulation, rapid offset of action) set it apart from other opioid agents. Remifentanyl is at least as effective as comparator opioids such as fentanyl, morphine and sufentanyl in providing pain relief and sedation in mechanically ventilated ICU patients. Moreover, it allows fast and predictable extubation, as well as being associated with a shorter duration of mechanical ventilation and quicker ICU discharge than comparators in some studies. In addition, remifentanyl is generally well tolerated in this patient population. Thus, remifentanyl is a welcome addition to the currently available pharmacological agents employed in the management of mechanically ventilated ICU patients.

## Disclosure

During the peer review process, the manufacturer of the agent under review was also offered an opportunity to comment on this article; changes based on any comments received were made on the basis of scientific and editorial merit.

## References

1. Gravel NR, Searle NR, Sahab PG, et al. Sedation in critically ill patients: practical recommendations. *CNS Drugs* 1999 Jan; 11 (1): 9-22
2. Park G. Remifentanyl in the ICU: a new approach to patient care. *Curr Anaesthes Crit Care* 2002; 13 (6): 313-20
3. Scott LJ, Perry CM. Remifentanyl: a review of its use during the induction and maintenance of general anaesthesia. *Drugs* 2005; 65 (13): 1793-823
4. Egan TD. Remifentanyl pharmacokinetics and pharmacodynamics: a preliminary appraisal. *Clin Pharmacokinet* 1995 Aug; 29 (2): 80-94
5. Cox EH, Langemeijer MWE, Gubbens-Stibbe JM, et al. The comparative pharmacodynamics of remifentanyl and its metabolite, GR90291, in a rat electroencephalographic model. *Anesthesiology* 1999 Feb; 90 (2): 535-44
6. Hoke JF, Cunningham F, James MK, et al. Comparative pharmacokinetics and pharmacodynamics of remifentanyl, its principle metabolite (GR90291) and alfentanil in dogs. *J Pharmacol Exp Ther* 1997; 281 (1): 226-32
7. Glass PSA, Hardman D, Kamiyama Y, et al. Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanyl (GI87084B). *Anesth Analg* 1993 Nov; 77 (5): 1031-40
8. Mason P. Remifentanyl. *Intensive Crit Care Nurs* 2002; 18: 355-7
9. Hoffman WE, Cunningham F, James MK, et al. Effects of remifentanyl, a new short-acting opioid, on cerebral blood flow, brain electrical activity, and intracranial pressure in dogs anesthetized with isoflurane and nitrous oxide. *Anesthesiology* 1993 Jul; 79 (1): 107-13
10. Breen D, Wilmer A, Bodenham A, et al. Offset of pharmacodynamic effects and safety of remifentanyl in intensive care unit patients with various degrees of renal impairment. *Crit Care* 2004 Feb; 8 (1): R21-30
11. Breen D, Karabinis A, Malbrain M, et al. Decreased duration of mechanical ventilation when comparing analgesia-based sedation using remifentanyl with standard hypnotic-based sedation for up to 10 days in intensive care unit patients: a randomised trial. *Crit Care* 2005 Jun; 9 (3): R200-10
12. Muellejans B, López A, Cross MH, et al. Remifentanyl versus fentanyl for analgesia based sedation to provide patient comfort in the intensive care unit: a randomized, double-blind controlled trial. *Crit Care* 2004 Feb; 8 (1): R1-11
13. Chinachoti T, Kessler P, Kirkham A, et al. Remifentanyl vs morphine for patients in intensive care unit who need short-term mechanical ventilation. *J Med Assoc Thai* 2002 Sep; 85 (Suppl. 3): 848-57
14. Karabinis A, Mandragos K, Stergiopoulos S, et al. Safety and efficacy of analgesia-based sedation with remifentanyl versus standard hypnotic-based regimens in intensive care unit patients with brain injuries: a randomised, controlled trial. *Crit Care* 2004 Aug; 8 (4): R268-80
15. Engelhard K, Reeker W, Kochs E, et al. Effect of remifentanyl on intracranial pressure and cerebral blood flow velocity in patients with head trauma. *Acta Anaesthesiol Scand* 2004 Apr; 48 (4): 396-9
16. Reeker W, Hanel F, Detsch O, et al. The effects of remifentanyl on systemic hemodynamic and EEG responses during endotracheal suctioning in ICU patients [abstract no. A203]. *Anesthesiology* 1997 Sep; 87 (3 Suppl.)
17. Cavaliere F, Antonelli M, Arcangeli A, et al. A low-dose remifentanyl infusion is well tolerated for sedation in mechani-

- cally ventilated, critically ill patients. *Can J Anesth* 2002 Dec; 49 (10): 1088-94
18. Dahaba AA, Grabner T, Rehak PH, et al. Remifentanyl versus morphine analgesia and sedation for mechanically ventilated critically ill patients: a randomized double blind study. *Anesthesiology* 2004 Sep; 101 (3): 640-6
  19. Leone M, Albanèse J, Viviani X, et al. The effects of remifentanyl on endotracheal suctioning-induced increases in intracranial pressure in head-injured patients. *Anesth Analg* 2004 Oct; 99 (4): 1193-8
  20. Glass PSA, Iselin-Chaves IA, Goodman D, et al. Determination of the potency of remifentanyl compared with alfentanil using ventilatory depression as the measure of opioid effect. *Anesthesiology* 1999 Jun; 90 (6): 1556-63
  21. Black ML, Hill JL, Zacny JP. Behavioral and physiological effects of remifentanyl and alfentanil in healthy volunteers. *Anesthesiology* 1999 Mar; 90 (3): 718-26
  22. Egan TD. Pharmacokinetics and pharmacodynamics of remifentanyl: an update in the year 2000. *Curr Opin Anaesthesiol* 2000; 13 (4): 449-55
  23. James MK, Feldman PL, Schuster SV, et al. Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues. *J Pharmacol Exp Ther* 1991; 259 (2): 712-8
  24. Amin HM, Sopchak AM, Esposito BF, et al. Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanyl or alfentanil. *J Pharmacol Exp Ther* 1995; 274 (1): 34-9
  25. Gustorff B, Felleiter P, Nahlik G, et al. The effect of remifentanyl on the heat pain threshold in volunteers. *Anesth Analg* 2001; 92: 369-74
  26. Petersen KL, Jones B, Segredo V, et al. Effect of remifentanyl on pain and secondary hyperalgesia associated with the heat-capsaicin sensitization model in healthy volunteers. *Anesthesiology* 2001 Jan; 94 (1): 15-20
  27. Curatolo M, Petersen-Felix S, Gerber A, et al. Remifentanyl inhibits muscular more than cutaneous pain in humans. *Br J Anaesth* 2000; 85 (4): 529-32
  28. Löttsch J, Angst MS. The  $\mu$ -opioid agonist remifentanyl attenuates hyperalgesia evoked by blunt and punctuated stimuli with different potency: a pharmacological evaluation of the freeze lesion in humans. *Pain* 2003; 102: 151-61
  29. Shinohara K, Aono H, Unruh GK, et al. Suppressing effects of remifentanyl on hemodynamics in baro-denervated rabbits. *Can J Anesth* 2000; 47 (4): 361-6
  30. James MK, Vuong A, Grizzle MK, et al. Hemodynamic effects of GI 87084B, an ultra-short acting  $\mu$ -opioid analgesic, in anesthetized dogs. *J Pharmacol Exp Ther* 1992; 263 (1): 84-91
  31. Sebel PS, Hoke JF, Westmoreland C, et al. Histamine concentrations and hemodynamic responses after remifentanyl. *Anesth Analg* 1995 May; 80 (5): 990-3
  32. Kazmaier S, Hanekop G-G, Buhre W, et al. Myocardial consequences of remifentanyl in patients with coronary artery disease. *Br J Anaesth* 2000 May; 84 (5): 578-83
  33. Noseir RK, Ficke DJ, Kundu A, et al. Sympathetic and vascular consequences from remifentanyl in humans. *Anesth Analg* 2003; 96: 1645-50
  34. Babenco HD, Conard PF, Gross JB. The pharmacodynamic effect of a remifentanyl bolus on ventilatory control. *Anesthesiology* 2000 Feb; 92 (2): 393-8
  35. Lorenz IH, Kolbitsch C, Schocke M, et al. Low-dose remifentanyl increases regional cerebral blood flow and regional cerebral blood volume, but decreases regional mean transit time and regional cerebrovascular resistance in volunteers. *Br J Anaesth* 2000 Aug; 85 (2): 199-204
  36. Paris A, Scholz J, von Knobelsdorff G, et al. The effect of remifentanyl on cerebral blood flow velocity. *Anesth Analg* 1998 Sep; 87: 569-73
  37. Klimscha W, Ullrich R, Nasel C, et al. High-dose remifentanyl does not impair cerebrovascular carbon dioxide reactivity in healthy male volunteers. *Anesthesiology* 2003 Oct; 99 (4): 834-40
  38. Ostapkovich ND, Baker KZ, Fogarty-Mack P, et al. Cerebral blood flow and CO<sub>2</sub> reactivity is similar during remifentanyl/N<sub>2</sub>O and fentanyl/N<sub>2</sub>O anesthesia. *Anesthesiology* 1998 Aug; 89 (2): 358-63
  39. Baker KZ, Ostapkovich N, Sisti MB, et al. Intact cerebral blood flow reactivity during remifentanyl/nitrous oxide anesthesia. *J Neurosurg Anesthesiol* 1997; 9 (2): 134-40
  40. Lorenz IH, Kolbitsch C, Hörmann C, et al. The effects of remifentanyl on cerebral capacity in awake volunteers. *Anesth Analg* 2000 Mar; 90 (3): 609-13
  41. Nieuwenhuijs DJF, Olofsen E, Romberg RR, et al. Response surface modeling of remifentanyl-propofol interaction in cardiorespiratory control and bispectral index. *Anesthesiology* 2003 Feb; 98 (2): 312-22
  42. Koitabashi T, Johansen JW, Sebel PS. Remifentanyl dose/electroencephalogram bispectral response during combined propofol/regional anesthesia. *Anesth Analg* 2002; 94: 1530-3
  43. Kan RE, Hughes SC, Rosen MA, et al. Intravenous remifentanyl: placental transfer, maternal and neonatal effects. *Anesthesiology* 1998 Jun; 88 (6): 1467-74
  44. Pitsiu M, Wilmer A, Bodenham A, et al. Pharmacokinetics of remifentanyl and its major metabolite, remifentanyl acid, in ICU patients with renal impairment. *Br J Anaesth* 2004 Apr; 92 (4): 493-503
  45. GlaxoSmithKline UK. Ultiva injection: summary of product characteristics [online]. Available from URL: <http://emc.medicines.org.uk> [Accessed 2005 Jul 18]
  46. Dahaba AA, Oettl K, von Klobucar F, et al. End-stage renal failure reduces central clearance and prolongs the elimination half life of remifentanyl. *Can J Anaesth* 2002 Apr; 49 (4): 369-74
  47. Dershwitz M, Hoke JF, Rosow CE, et al. Pharmacokinetics and pharmacodynamics of remifentanyl in volunteer subjects with severe liver disease. *Anesthesiology* 1996 Apr; 84 (4): 812-20
  48. Westmoreland CL, Hoke JF, Sebel PS, et al. Pharmacokinetics of remifentanyl (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. *Anesthesiology* 1993 Nov; 79 (5): 893-903
  49. Bouillon T, Bruhn J, Radu-Radulescu L, et al. Non-steady state analysis of the pharmacokinetic interaction between propofol and remifentanyl. *Anesthesiology* 2002 Dec; 97 (6): 1350-62
  50. Ross AK, Davis PJ, Dear GDL, et al. Pharmacokinetics of remifentanyl in anesthetized pediatric patients undergoing elective surgery or diagnostic procedures. *Anesth Analg* 2001; 93: 1393-401
  51. Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanyl. I. Model development. *Anesthesiology* 1997 Jan; 86 (1): 10-23
  52. Wilhelm W, Dorscheid E, Schlaich N, et al. Remifentanyl zur analgosedierung von intensivpatienten. *Anaesthesist* 1999; 48: 625-9
  53. Royston D, Kirkham A, Adt M, et al. Extubation following CABG using remifentanyl based total intravenous anesthesia

- (TIVA) [abstract no. A239]. *Anesthesiology* 1996 Sep; 83 (3A Suppl.)
54. Morrison L, Binning AR, Bodenham AR, et al. Remifentanyl versus fentanyl in providing optimal sedation in post-surgical ICU patients: preliminary results [abstract no. 354]. 13th Annual Congress of the European Society of Intensive Care Medicine; 2000 Oct 1-4; Rome
55. Davidson A, Skolka M, Kessler P, et al. Remifentanyl vs. morphine for the provision of optimal sedation in ICU patients: preliminary results [abstract no. A-405]. *Eur J Anaesthesiol* 2001; 18 Suppl. 21: 114-5
56. Howie MB, Cheng D, Newman MF, et al. A randomized double-blinded multicenter comparison of remifentanyl versus fentanyl when combined with isoflurane/propofol for early extubation in coronary artery bypass graft surgery. *Anesth Analg* 2001 May; 92 (5): 1084-93
57. Matthey T, Schill M, Muellejans B. Earlier discharge from ICU with remifentanyl/propofol versus fentanyl/midazolam [abstract]. *Intensive Care Med* 2004; 30 Suppl. 1: 174
58. Soltesz S, Biedler A, Silomon M, et al. Recovery after remifentanyl and sufentanil for analgesia and sedation of mechanically ventilated patients after trauma or major surgery. *Br J Anaesth* 2001 Jun; 86 (6): 763-8
59. Baillard C, Cohen Y, Le Toumelin P, et al. Rémifentanyl-midazolam versus sufentanil-midazolam pour la sédation prolongée en réanimation. *Ann Fr Anesth Reanim* 2005 May; 24 (5): 480-6
60. Wilhelm W, Wrobel M, Ketter R, et al. Remifentanyl/propofol versus fentanyl/midazolam for ICU sedation [abstract no. A705]. *Eur J Anaesthesiol* 2004; 21 Suppl. 32
61. Akinci SB, Kanbak M, Guler A, et al. Remifentanyl versus fentanyl for short-term analgesia-based sedation in mechanically ventilated postoperative children. *Paediatr Anaesth* 2005 Oct; 15 (10): 870-8
62. Stoppa F, Perrotta D, Tomasello C, et al. Low dose remifentanyl infusion for analgesia and sedation in ventilated newborns. *Minerva Anesthesiol* 2004 Nov; 70 (11): 753-61
63. Andel H, Felfernig M, Knabl J, et al. Erste erfahrungen mit der langzeitanwendung von remifentanyl auf der intensivpflegestation für brandverletzte. *Anästh Intensivmed* 2000; 41: 674-8
64. Tipps LB, Coplin WM, Murry KR, et al. Safety and feasibility of continuous infusion of remifentanyl in the neurosurgical intensive care unit. *Neurosurgery* 2000 Mar; 46 (3): 596-602
65. Müllejans B, Matthey T, Schill M, et al. Pharmacoeconomic evaluation of sedation with remifentanyl/propofol versus midazolam/fentanyl in the intensive care unit [abstract no. DN4 plus oral presentation]. 8th Annual Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2005 Nov 6-8; Florence
66. Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. *Ann Intern Med* 1998 Sep 15; 129 (6): 433-40
67. Rello J, Paiva JA, Baraibar J, et al. International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. *Chest* 2001 Sep; 120 (3): 955-70
68. Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. *Crit Care Med* 2003; 31 (5): 1312-7
69. Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill patient. *Crit Care Med* 2002; 30 (1): 119-41
70. Samuelson KA, Larsson S, Lundberg D, et al. Intensive care sedation of mechanically ventilated patients: a national Swedish survey. *Intensive Crit Care Nurs* 2003 Dec; 19 (6): 350-62
71. Park G. Improving sedation and analgesia in the critically ill. *Minerva Anesthesiol* 2002; 68 (6): 505-12
72. Malbrain M. Remifentanyl use in the ICU: a health economic viewpoint. *ICU Management* 2005; 5 (2): 22-4
73. Liu LL, Gropper MA. Postoperative analgesia and sedation in the adult intensive care unit: a guide to drug selection. *Drugs* 2003; 63 (8): 755-67
74. Cohen J, Royston D. Remifentanyl. *Curr Opin Crit Care* 2001 Aug; 7 (4): 227-31
75. MacIntyre NR, Cook DJ, Ely EW, et al. Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine. *Chest* 2001 Dec; 120 (6 Suppl.): 375-95S
76. Wolf AR, Potter F. Propofol infusion in children: when does an anesthetic tool become an intensive care liability? *Paediatr Anaesth* 2004 Jun; 14 (6): 435-8
77. Holzki J, Arnig C, Gillor A. Death after re-exposure to propofol in a 3-year-old child: a case report. *Paediatr Anaesth* 2004 Mar; 14 (3): 265-70
78. Annane D, Bellissant E, Cavaillon J-M. Septic shock. *Lancet* 2005 Jan 1; 365: 63-78
79. Vender JS, Szokol JW, Murphy GS, et al. Sedation, analgesia, and neuromuscular blockade in sepsis: an evidence-based review. *Crit Care Med* 2004; 32 (11 Suppl.): S554-61

---

Correspondence: Gillian M. Keating, Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand.  
E-mail: demail@adis.co.nz